Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic ...

These patients had a predicted 30-day mortality risk <3%, as assessed by a local heart team. 1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or ...

DUBLIN, May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial ...

TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial DUBLIN and SAN FRANCISCO, Oct. 24, 2023 /PRNewswire ...

DUBLIN -- Medtronic plc today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native ...

The data showed Evolut’s approach was not inferior to surgery when it came to a combined rate of death or disabling stroke after the procedure, with 4.3% for TAVR and 6.3% for surgery.

However, , compared to a balloon-expandable valve, the Evolut SEV was associated with significantly less BVD (8.4% vs. 41.8% at 12 months), less prosthesis-patient mismatch (11.1% vs. 37.4% at 12 ...

Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the ...

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients Provided by PR Newswire Mar 30, 2025, 8:00:00 AM ...